Nuvalent, Inc. Profile Avatar - Palmy Investing

Nuvalent, Inc.

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]

Filings / Resources

Link Index · Filing Reader · 10K/10Q
Loading may take some time.
SEC
2024-03-31 2023-12-31 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30
Transcripts

Gather insights into the latest earnings call through our transcripts.

Other Docs/Resources
Transcripts Investor Relations EDGAR NUVL's Industry Healthcare Analysis Biotechnology Analysis US Analysis Cambridge Analysis
End of NUVL's Analysis
CIK: 1861560 CUSIP: 670703107 ISIN: US6707031075 LEI: - UEI: -
Secondary Listings
NUVL has no secondary listings inside our databases.